TABLE 1.

Patient data ^a with specification of tumors and cfDNA content in CSF.

#	Age of onset	Gender	Integrated diagnosis b	Tumor volume, cm3 c	Time of CSF collection	CSF collection procedure	CSF sample volume, ml	37 bp fragment concentration, copies/µl	150 bp fragment concentration, copies/µl	300 bp fragment concentration, copies/µl	H3 K27M in tumor tissue	H3 K27M in CSF
1	5 months	Female	Infant-type hemispheric glioma, ETV6-NTRK3-positive	345	Primary	VAD	3	16,793	15,170	8,583	-	-
2	3 months	Female	Atypical teratoid/rhabdoid tumor, SMARCB1-mutant	99.5	During therapy	VAD	2.4	2,972	1,486	546	-	-
3	2 years 10 months	Male	Atypical teratoid/rhabdoid tumor, NOS	9.5	During therapy	VAD	2.8	676	417	306	-	-
4	1 year 11 months	Female	Anaplastic medulloblastoma, non-WNT/non-SHH	12.2	During therapy	VAD	4	361	122	101	-	-
5	5 years 5 months	Male	Desmoplastic medulloblastoma, SHH-activated, TP53-wildtype, PTCH1-mutant	0.44	Metastatic relapse	VAD	2.5	53	35	20	-	-
6	11 years 5 months	Male	Medulloblastoma, non-WNT/non-SHH	26.3	Primary	IO	2	0	0	0	-	NA
7	5 years 2 months	Male	Posterior fossa ependymoma, group PFA	2.2	Local relapse	IO	4	973	683	669	-	-
8	10 years 8 months	Male	Diffuse pediatric-type high-grade glioma, H3-wildtype, and IDH-wildtype	140	Primary	IO	4	64	47	142	-	-
9	11 years 11 months	Female	Diffuse midline glioma, H3 K27-altered	37.4	After surgery	LP	3	16	10	0	+	+
10	5 years 1 month	Male	Diffuse midline glioma, H3 K27-altered	16	Primary	LP	2	1	3	4	+	?
11	5 years 7 months	Male	Diffuse midline glioma, H3 K27-altered	14	Primary	IO	13.3	66	108	87	+	+
								320	165	137
						LP	1	4	7	3		?
12	11 years 2 months	Male	Diffuse midline glioma, H3 K27-altered	87	Primary	IO	10	27	14	6	+	+
								19	8	9
13	6 years 9 months	Male	Optic chiasm pilocytic astrocytoma, NOS	10	Primary	VAD	5	106	81	51	NA	-
14	1 month	Male	Pilocytic astrocytoma, KIAA1549 (exon 15)—BRAF (exon 9)—positive	134	During therapy	VAD	4.8	387	108	67	-	-
15	7 years 3 months	Male	Pilocytic astrocytoma, KIAA1549 (exon 16)—BRAF (exon 9)—positive	2.9	Primary	LP	3.5	0	0	0	—	NA
16	9 months	Female	Pilocytic astrocytoma, KIAA1549 (exon 15)—BRAF (exon 9)—positive	74	Local relapse	IO	1.2	0	0	0	—	NA
17	8 years 8 months	Female	Histologically unverified bilateral thalamic tumor with midbrain extension (suspected high-grade glioma)	142	Primary	VAD	2	9	6	0	NA	-
18	4 years 10 months	Female	Histologically unverified tumor of the right cerebral peduncle and basal ganglia on the right (suspected low-grade glioma)	16.4	Primary	LP	2	2	0	0	NA	NA

^aSorted roughly by morphological assignment.

^bBased on the 2021 WHO Classification of Tumors of the Central Nervous System [15].

^cTumor volume at the time of CSF collection.

NA, no data available; VAD, ventricular access device; IO, intraoperatively; LP, lumbar puncture.